MEK inhibitors also displayed preclinical antitumor activity and prospective clinical studies as well as case studies found promising responses, particularly in patients with NF1-associated plexiform neurofibromatosis, a precancerous lesion for MPNST (Gross et al. 2018; Vaassen et al. 2019; Nagabushan et al. 2021; Peacock et al. 2018). The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.